Ionis, AstraZeneca eplontersen application accepted by FDA for nerve damage disorder
designer491/iStock via Getty Images         

The US FDA has accepted a New Drug Application submitted by Ionis Pharmaceuticals (NASDAQ:IONS) forÂ eplontersen for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
The FDA action date is Dec. 22.
The agency said it does not plan on holding an advisory committee meeting for the application.
Ionis (IONS) is partnered with AstraZeneca (NASDAQ:AZN) on the candidate.
Ionis (IONS) said that patients with ATTRv-PN experience ongoing debilitating nerve damage throughout the body resulting in the progressive loss of motor function.
Read why Seeking Alpha contributor Out of Ignorance rates Ionis (IONS) a hold.